To resect or not to resect? That is the question
- 1Liver Diseases Branch, The National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Maryland, USA
- 2Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Maryland, USA
- 3Integrative Cardiovascular Imaging Section, The National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Maryland, USA
- 4Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Maryland, USA
- Correspondence to Dr Mazen Noureddin, Liver Diseases Branch, The National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Bldg 10 Room 4-5722, Clinical Center, Bethesda, Maryland 20892, USA;
A 54-year-old Caucasian female, with a strong family history of renal cell carcinoma, presented with a left kidney lesion. She had a hysterectomy 20 years ago and no significant history of oral contraceptive use. During the current evaluation, she was found to have two hypervascular lesions in the left lobe of the liver in addition to a fatty liver on CT scan as well as MRI (figure 1A–C). The largest lesion was 2 cm in size. She was asymptomatic. Physical examination showed an obese woman with body mass index of 35.6 with an otherwise normal exam. Her laboratory results showed an aspartate aminotransferase of 88 U/l, alanine aminotransferase of 75 U/l, alkaline phosphatase of 93 U/l, total bilirubin of 0.6 mg/dl and direct bilirubin of 0.2 mg/dl. Her albumin, leucocytes, haemoglobin and platelets were all normal. She underwent a left nephrectomy. She also underwent a hepatectomy of segments 2 and 3 due to suspicion of metastatic disease. The pathology from the liver lesions is shown in figures 2 and 3.
What is the diagnosis of the liver lesions?
See page 1235 for answer
From the question on page 1177
Figure 4 shows an irregular distribution of steatotic hepatic parenchyma with dilated vessels embedded within a fibrosis stroma. The surrounding liver showed steatohepatitis and early fibrosis. These are the typical pathological findings of telangiectatic adenoma (TA).
Benign hepatic liver tumours are classically divided into hepatic adenoma (HA) and focal nodular hyperplasia (FNH). Telangiectatic adenomas (TAs) were originally classified as telangiectatic focal nodular hyperplasia. Recent molecular studies have led pathologists to reclassify telangiectatic adenoma as hepatic adenomas.1 TA is typically associated with obesity and steatosis.2 Paradis et al showed that 19% of TA had cellular atypia and one of them had hepatocellular carcinoma (HCC). Other reports have also suggested that TA is associated with obesity and may progress to HCC.3 Dokmak et al showed that 10% of TAs progressed to HCC. This risk was associated with an adenoma size of larger than 5 cm.4 Our patient had TA that was associated with steatohepatitis and obesity. TA should be suspected when mass lesions are discovered in the setting of obese patients with evidence of fatty liver disease. This is particularly important given recent advances in classification of adenomas and evidence for the development of possible malignancy.
Funding The Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and NIDDK.
Competing interests None.
Patient consent Obtained.
Ethics approval This study was conducted with the approval of the NIH IRB.
Provenance and peer review Not commissioned; externally peer reviewed.